Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF17, J6M0 Vector   (CAT#: GTVCR-WQ1600MR)

This product GTVCR-WQ1600MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting TNFRSF17. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Humanized
RefSeq NM_001192.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF17, J6M0 Vector (GTVCR-WQ1600MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ366MR IVTScrip™ pSP6-VEE-mRNA-Anti-CGRP, ALD-403 Vector Vector ALD-403
GTVCR-WQ2316MR IVTScrip™ pT7-VEE-mRNA-Anti-GCGR, REGN-1193 Vector Vector REGN-1193
GTVCR-WQ1176MR IVTScrip™ pT7-VEE-mRNA-Anti-CSF3R, F-627 Vector Vector F-627
GTVCR-WQ361MR IVTScrip™ pSP6-VEE-mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608) Vector Vector Alb-IFNA2 R23 (608)
GTVCR-WQ228MR IVTScrip™ pT7-VEE-mRNA-Anti-MET, ABT-700 Vector Vector ABT-700
GTVCR-WQ1888MR IVTScrip™ pT7-VEE-mRNA-Anti-hly, MEDI4893 Vector Vector MEDI4893
GTVCR-WQ1070MR IVTScrip™ pSP6-VEE-mRNA-Anti-MSTN, CSL-362-AML Vector Vector CSL-362-AML
GTVCR-WQ1546MR IVTScrip™ pSP6-VEE-mRNA-Anti-MS4A1, IMMU-106 Vector Vector IMMU-106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW